Affordable Access

[Malignant lymphomas].

Authors
Type
Published Article
Journal
Gan to kagaku ryoho. Cancer & chemotherapy
Publication Date
Volume
36
Issue
5
Pages
736–741
Identifiers
PMID: 19461173
Source
Medline

Abstract

Treatment outcome of malignant lymphomas has been improved since molecular targeted drugs including rituximab became clinically available. However, treatment for relapsed or refractory lymphoma has not been fully established. As second-line therapy for patients with relapsed/refractory follicular lymphoma or diffuse large B cell lymphoma, chemotherapy including alkylating agents or purine analogues, high-dose chemotherapy followed by autologous stem cell transplantation (SCT), and allogeneic SCT are usually selected. Recently, we can also select new therapies including new anti-CD20 monoclonal antibody (MoAb)(IMMU-106(hA20)), anti-CD22 MoAb (epratuzumab), and radioimmunotherapy including Y-90 ibritumomab and I-131 tositumomab.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments